Epidemiological Study on Malignancy Complicated With Renal Injury

The epidemiological study of tumor complicated with kidney disease can clarify the prevalence and risk factors of renal injury when malignant tumor is diagnosed, and understand the impact of malignant tumor complicated with renal injury on survival time. This study will bring enlightenment to clinicians, discover high-risk factors in time, and try to avoid renal damage factors in diagnosis and treatment. Early diagnosis and early treatment can partially terminate the progress of renal injury, avoid the suspension of treatment due to renal reasons, and avoid the occurrence of end-stage renal failure (ESRD).

Study Overview

• Status: Not yet recruiting
• Conditions: Kidney Injury

Detailed Description

1. To determine the prevalence of malignant tumor complicated with renal injury and analyze the related risk factors.
2. To compare the survival time of malignant tumor with or without renal injury

• Study Type: Observational
• Enrollment (Anticipated): 30000

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

Patients initially diagnosed with malignancy in Shanghai Renji Hospital from July 2017 to June 2021

Description

Inclusion Criteria:

• Malignancy confirmed by pathology.
• Between 18-80 years old, regardless of gender; Patients initially diagnosed with malignant tumors in our hospital from July 2017 to June 2021; Waiver of informed consent.

Exclusion Criteria:

• Patients with benign tumor diagnosed by pathology; The patient refused to participate; Patients judged by other researchers as unsuitable for inclusion in the study.

Study Plan

How is the study designed?

Number of groups / cohorts

2

Cohorts and Interventions

Group / Cohort
Normal renal function group; Observe survival time
Renal dysfunction group; Observe survival time

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
survival	survival time	3 years

Collaborators and Investigators

• Sponsor: RenJi Hospital

Study record dates

Study Major Dates

• Study Start (Anticipated): December 1, 2022
• Primary Completion (Anticipated): December 1, 2024
• Study Completion (Anticipated): December 1, 2024

Study Registration Dates

• First Submitted: May 23, 2022
• First Submitted That Met QC Criteria: May 23, 2022
• First Posted (Actual): May 26, 2022

Study Record Updates

• Last Update Posted (Actual): May 26, 2022
• Last Update Submitted That Met QC Criteria: May 23, 2022
• Last Verified: May 1, 2022

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Wounds and Injuries
• Other Study ID Numbers: KY2021-253-B

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No